Skip to main content
Clinical Trials/NCT01225952
NCT01225952
Completed
Phase 4

A Three Arm Prospective Clinical Evaluation of Three FDA-approved Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction

Bausch & Lomb Incorporated1 site in 1 country93 target enrollmentJuly 2010
ConditionsCataract

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Cataract
Sponsor
Bausch & Lomb Incorporated
Enrollment
93
Locations
1
Primary Endpoint
Monocular Mesopic Contrast Sensitivity Without Glare(12 Cycles/Degree)
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

The objective of this study is to compare the contrast sensitivity, high and low contrast visual acuity (VA), glare meter outcomes, and subject satisfaction with three different FDA-approved intraocular lenses (IOLs) designed to improve distance, intermediate, and near vision following lens extraction in adults at least 40 years of age.

Registry
clinicaltrials.gov
Start Date
July 2010
End Date
July 2011
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects must be undergoing primary IOL implantation for the correction of aphakia following continuous curvilinear anterior capsulotomy and phacoemulsification cataract extraction.
  • Subjects must require a spherical lens power from 10.00 diopters (D) to 33.00 D.
  • Subjects must have the potential for corrected distance visual acuity (CDVA) of 20/32 or better in both eyes.
  • Subjects must have stopped contact lens wear for at least two weeks for soft lens wearers or three weeks for gas permeable lens wearers prior to biometry and surgery.
  • At the time of surgery, subjects must have an intact centered capsulorhexis, intact posterior capsule, and no zonular rupture.
  • Subjects must have ≤ 1.25 D of preoperative corneal astigmatism in both eyes.

Exclusion Criteria

  • Subjects with diagnoses of degenerative visual disorders (eg, macular degeneration, or other retinal disorders) that cause potential acuity losses to a level of 20/32 or worse.
  • Subjects with conditions with increased risk of zonular rupture, such as pseudoexfoliation syndrome.
  • Subjects who have any active inflammation or edema (swelling) of the cornea, including but not limited to the following: keratitis, keratoconjunctivitis, and keratouveitis.
  • Subjects with uncontrolled glaucoma.
  • Subjects with previous retinal detachment.
  • Subjects with visually significant diabetic retinopathy (proliferative or nonproliferative) which reduces potential acuity to 20/32 or worse.
  • Subjects with rubella, bilateral congenital, traumatic, complicated or polar cataract.
  • Subjects with marked microphthalmos or aniridia.
  • Subjects who have had previous corneal surgery.
  • Subjects with irregular corneal astigmatism.

Outcomes

Primary Outcomes

Monocular Mesopic Contrast Sensitivity Without Glare(12 Cycles/Degree)

Time Frame: Postoperative visit 4 (day 120-180)

A single eye (monocular) in dim light (mesopic) measuring contrast sensitivity; The participant is presented with a sine-wave grating target of a given spatial frequency (cycles/degree of visual angle) where the smaller the number of cycles/degree the wider apart the gradations (vertical lines of grayness). The participant's ability to detect changes in contrast is determined. Higher mean indicates improved contrast sensitivity.

Monocular Mesopic Contrast Sensitivity Without Glare(1.5, 3 Cycles/Degree)

Time Frame: Postoperative visit 4 (day 120-180)

A single eye (monocular) in dim light (mesopic) measuring contrast sensitivity; The participant is presented with a sine-wave grating target of a given spatial frequency (cycles/degree of visual angle) where the smaller the number of cycles/degree the wider apart the gradations (vertical lines of grayness). The participant's ability to detect changes in contrast is determined. Higher mean indicates improved contrast sensitivity.

Monocular Mesopic Contrast Sensitivity Without Glare (1.5, 3 Cycles/Degree)

Time Frame: Postoperative visit 3 (day 30-60)

A single eye (monocular) in dim light (mesopic) measuring contrast sensitivity; The participant is presented with a sine-wave grating target of a given spatial frequency (cycles/degree of visual angle) where the smaller the number of cycles/degree the wider apart the gradations (vertical lines of grayness). The participant's ability to detect changes in contrast is determined. Higher mean indicates improved contrast sensitivity.

Monocular Mesopic Contrast Sensitivity Without Glare(18 Cycles/Degree)

Time Frame: Postoperative visit 4 (day 120-180)

A single eye (monocular) in dim light (mesopic) measuring contrast sensitivity; The participant is presented with a sine-wave grating target of a given spatial frequency (cycles/degree of visual angle) where the smaller the number of cycles/degree the wider apart the gradations (vertical lines of grayness). The participant's ability to detect changes in contrast is determined. Higher mean indicates improved contrast sensitivity.

Monocular Mesopic Contrast Sensitivity Without Glare(6 Cycles/Degree)

Time Frame: Postoperative visit 4 (day 120-180)

A single eye (monocular) in dim light (mesopic) measuring contrast sensitivity; The participant is presented with a sine-wave grating target of a given spatial frequency (cycles/degree of visual angle) where the smaller the number of cycles/degree the wider apart the gradations (vertical lines of grayness). The participant's ability to detect changes in contrast is determined. Higher mean indicates improved contrast sensitivity.

Secondary Outcomes

  • Monocular Mesopic Contrast Sensitivity With Glare(6 Cycles/Degree)(Postoperative visit 4 (day 120-180))
  • Binocular Mesopic Contrast Sensitivity Without Glare(18 Cycles/Degree)(Postoperative visit 4 (day 120-180))
  • Monocular Mesopic Contrast Sensitivity With Glare (3 Cycles/Degree)(Postoperative visit 3 (day 30-60))
  • Monocular Mesopic Contrast Sensitivity With Glare(18 Cycles/Degree)(Postoperative visit 4 (day 120-180))
  • Monocular Mesopic Contrast Sensitivity With Glare(3 Cycles/Degree)(Postoperative visit 4 (day 120-180))
  • Binocular Mesopic Contrast Sensitivity Without Glare(1.5, 3 Cycles/Degree)(Postoperative visit 4 (day 120-180))
  • Monocular Mesopic Contrast Sensitivity With Glare(1.5 Cycles/Degree)(Postoperative visit 4 (day 120-180))
  • Binocular Mesopic Contrast Sensitivity Without Glare(6 Cycles/Degree)(Postoperative visit 4 (day 120-180))
  • Binocular Mesopic Contrast Sensitivity Without Glare(12 Cycles/Degree)(Postoperative visit 4 (day 120-180))
  • Monocular Mesopic Contrast Sensitivity With Glare(12 Cycles/Degree)(Postoperative visit 4 (day 120-180))

Study Sites (1)

Loading locations...

Similar Trials